Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q3 EPS of ($1.17), $0.18 worse than the analyst estimate of ($0.99). Revenue for the quarter came in at $110.4 million versus the consensus estimate of $99.38 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.